Related Experiment Video
Updated: Aug 21, 2026
Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
Published on: August 26, 2025
Optimal duration of eptifibatide infusion in percutaneous coronary intervention (an ESPRIT substudy)
Abdallah G Rebeiz1, Jean-Pierre Dery, Anastasios A Tsiatis
1Duke Clinical Research Institute, Durham, North Carolina, USA.
Insights
This study investigated the ideal infusion duration for eptifibatide after percutaneous coronary intervention (PCI). Findings aim to optimize treatment and reduce healthcare costs by determining the most effective infusion length for this antiplatelet therapy.
Area of Science:
- Cardiology
- Pharmacology
- Interventional Cardiology
Background:
- Platelet glycoprotein IIb/IIIa antagonists are clinically effective in percutaneous coronary intervention (PCI).
- Optimal infusion duration for these agents post-PCI remains undetermined.
- Hospitalization length significantly impacts healthcare costs.
Purpose of the Study:
- To determine the optimal infusion duration of eptifibatide following PCI.
- To analyze patient outcomes based on randomized eptifibatide infusion lengths.
- To inform cost-effective treatment strategies in interventional cardiology.
Main Methods:
- Analysis of patient outcomes from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial.
- Patients were randomized to varying durations of eptifibatide infusion post-PCI.
- Outcomes were assessed to identify the most effective infusion period.
Main Results:
- Data on specific outcomes related to infusion duration are presented.
- The study provides insights into the efficacy of different eptifibatide infusion lengths.
- Results contribute to understanding the balance between efficacy and treatment duration.
Conclusions:
- The optimal infusion duration of eptifibatide post-PCI was investigated.
- Findings aim to guide clinical practice for improved patient outcomes and cost efficiency.
- Further analysis of the ESPRIT trial data provides evidence for treatment optimization.
Abstract:
Although randomized trials have clearly demonstrated the clinical efficacy with regimens of platelet glycoprotein IIb/IIIa antagonists that result in >80% inhibition of baseline platelet aggregation in percutaneous coronary intervention (PCI), there are no data available concerning the optimal duration of infusion of these agents. In an era when the length of hospitalization has a major impact on health care costs, the determination of the optimal duration of the infusion of these drugs after PCI is of great relevance. The investigators therefore sought to determine the optimal length of the infusion of eptifibatide after PCI by analyzing the outcomes of patients enrolled in the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy trial who were randomized to treatment with eptifibatide.
